Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14116755 | 0.84 | CYP17A1 (0.42) | MAPK14CYP17A1ATRGSK3BDYRK1A | |
| SCHEMBL14116754 | 0.81 | ATR (0.43) | MAPK14CYP17A1ATRGSK3BDYRK1A | |
| SCHEMBL6292251 | 0.81 | CYP17A1 (0.40) | MAPK14CYP17A1ATRGSK3BDYRK1A | |
| SCHEMBL17873733 | 0.80 | CYP17A1 (0.39) | MAPK14CYP17A1ATRGSK3BDYRK1A | |
| SCHEMBL25007594 | 0.80 | CTSK (0.51) | KMT2ACTSKPOLBMAPK14HPGDS | |
| SCHEMBL19373777 | 0.80 | CYP17A1 (0.40) | KMT2ACTSKMAPK14CYP17A1ATR | |
| SCHEMBL23284005 | 0.79 | KMT2A (0.50) | KMT2ACTSKPOLBMAPK14HSP90AA1 | |
| SCHEMBL31437460 | 0.79 | GSK3B (0.41) | CTSKMAPK14CYP17A1ATRGSK3B | |
| SCHEMBL27001165 | 0.78 | KMT2A (0.53) | KMT2ACTSKPOLBHPGDSHSP90AA1 | |
| SCHEMBL17837279 | 0.78 | BRD4 (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152014-B2 | Therapeutic compounds and compositions | eXlthera Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| CN-112638917-B | Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof | 捷思英达控股有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4206199-A1 | AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-112457326-B | Aromatic heterocyclic lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-110950876-B | Furanolactam compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| CN-112638917-A | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compounds, and methods of use thereof | 捷思英达控股有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112457326-A | Aromatic heterocyclic lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3749662-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-111902404-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-110950876-A | Furanolactam compounds, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-04-03 | — | — | CN | disclosed |
| WO-2019156929-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019156929-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2016095088-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | KMT2A 874/4885CTSK 63/4885POLB 4497/4885 |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | KMT2A 874/4885CTSK 63/4885POLB 4497/4885 |
| US-12152014-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | KMT2A 874/4885CTSK 63/4885POLB 4497/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | KMT2A 874/4885CTSK 63/4885POLB 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.